Bertis Publishes Result on Proteomic Based Research of New Biomarker for the Diagnosis of Ovarian Cancer
- The research team has presented results of a new multi-biomarker panel candidate with high accuracy (95%) for the diagnosis of stage 1 to 3 high-grade serous ovarian cancer
- The results were included as 16 papers listed supplementary cover articles in the Sep issue of the international scientific journal, Journal of Proteome Research
- As a result of developing and evaluating a predictive model, the accuracy of the diagnostic value for stages 1 to 3 HGSOC was 95% (sensitivity 100%, specificity 91%) when 18 candidate proteins were combined with multiple biomarkers that were identified after quantifying 1,847 serum proteins, through Bertis’ advanced proteomics analysis technology
Ref: Businesswire | Image: Bertis
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.